Nanobac, Mayo Clinic to study calcifying nanoparticles in heart disease

By Lisa Kerner

Charlotte, N.C., Sept. 25 - Nanobac Pharmaceuticals, Inc. and the Mayo Clinic agreed to conduct a landmark study of calcifying nanoparticles in heart disease.

The study follows published findings that show these nanoparticles may provoke stone-forming disease in an animal model. Similar studies are ongoing in the United States, China and Finland.

Nanobac is a life sciences company based in Tampa, Fla.

The Mayo Clinic is a not-for-profit medical practice with locations in Minnesota and Arizona.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.